Japanese drugmaker Kyowa Hakko Kirin and Denmark’s privately-held dermatology specialist LEO Pharma have entered into a distribution and co-promotion agreement for LEO’s proprietary topical calcipotriol/betamethasone dipropionate combination product. 26 December 2013
Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP; December 16-19), there were positive opinions for four investigational drugs issued on Friday. 22 December 2013
Privately-held Italian drugmaker Angelini and Switzerland-based health care group Applied Pharma Research (APR) have entered into a strategic partnership to support and promote a novel and innovative product developed by APR for the management of a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers. 20 December 2013
Spain’s largest drugmaker, Almirall says it has reached a definitive agreement to acquire Aqua Pharmaceuticals, a privately-held leading US-based prescription dermatology company. 17 December 2013
Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion in 2012 to $5.6 billion by 2022 according to research and consulting firm GlobalData. 15 November 2013
Belgian biotech firm Galapagos says that a subsidiary has signed a three-year collaboration agreement with US biotech Biogen Idec focused on the identification and validation of novel targets in scleroderma. 13 November 2013
The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full exit from Tunisian pharmaceutical company Opalia Pharma. 5 November 2013
Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor, both of which were seen as promising for the company’s future. 25 October 2013
US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation to begin a Phase IIb clinical trial of Brilacidin as a new drug candidate for acute bacterial skin and Skin structure infections. 14 October 2013
Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis. 9 October 2013
Novartis recently announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to US biotech leader Amgen’s Enbrel (etanercept) in moderate-to-severe plaque psoriasis. 8 October 2013
Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria (CSU), a chronic and debilitating form of hives. 5 October 2013
Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE) into isavuconazole, the antifungal agent being co-developed with Basilea Pharmaceutica. 30 September 2013
Singapore is committing close to S$100 million ($79.6 million) to skin research, announced the Skin Research Institute of Singapore today. 27 September 2013
Privately-held Danish dermatology specialist LEO Pharma has announced the completion of a Phase III study to assess treatment with ingenol mebutate gel for actinic keratosis (AK). 26 September 2013
US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from $34 by Leerink analysts and an outperform rating and $50 target by Cowen analysts, after the company said that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. The shares rose 29% to $43.24 in pre-market trading today (September 17). 17 September 2013
Luliconazole, a medication approved in Japan for the treatment of superficial mycosis in a 1% formulation, was not associated with any serious side effects when used in a 10% formulation to treat toenail fungus. 16 September 2013
Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says it has made a significant achievement within the RORgamma project, triggering the first milestone payment (amount not disclosed) to Karo Bio. 6 September 2013
USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources on the completion of three lead clinical programs, a move which follows recent disappointing clinical results with the company's asthma drug candidate R343 (The Pharma Letter August 27). 5 September 2013
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today (September 2) announced positive full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. 2 September 2013
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024